Mainland China's total number of confirmed coronavirus cases hits 80,967 as of end-March 19 – Reuters News
|The latest data in China's COVID-19 cases is out and there is another consecutive day where Hubei province reports zero new cases on March 19 vs zero on March 18.
- Mainland China reports 39 new confirmed cases of coronavirus on March 19 vs 34 on March 18.
- Mainland China reports 3 new coronavirus deaths on march 19 vs 8 on March 18.
- Mainland China's total number of confirmed coronavirus cases hits 80,967 as of end-March 19.
- Mainland China's total number of coronavirus deaths reaches 3,248 as of end-March 19.
- Mainland China's imported coronavirus cases at 228 as of end-march 19, up 39 from day earlier.
- China's Hubei province reports zero new cases on march 19 vs zero on March 18.
- China's Hubei province reports 2 new deaths on march 19 vs 8 on March 18.
- Death toll from coronavirus outbreak in china's Hubei at 3,132 as of end-March 19.
- Beijing recorded six imported COVID19 infections on Thursday, one from the #US and five from the UK, totaling the capital’s imported cases to 70.
Market implications
It is good news that the prior epicentre if COVID-19 is in recovery:
However, Italy is going through the apocalypse, now the world epicentre of COVID-19 and the rest of the world's case are growing exponentially:
Markets in the US were slightly higher on Thursday, but risks are firmly skewed tot he downside with another 65% of losses to go until the 2008 lows in the Dow: Wall Street Close: Benchmarks higher in corrective and choppy markets
On the upside, following on from yesterday's news, Remdesivir could be approved very soon for COVID-19, while speaking to reporters at a news conference at the White House, US President Donald Trump said Gilead's Remdesivir seems to have very good results fighting the coronavirus. Gilead Sciences' shares rose sharply following these comments but the company hasn't yet published an official statement on the experimental COVID-19 therapy.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.